10x Genomics (NASDAQ:TXG) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of 10x Genomics (NASDAQ:TXG) from a hold rating to a buy rating in a research note published on Friday morning.

Several other analysts also recently weighed in on TXG. Barclays reissued an “overweight” rating and issued a $15.00 target price (up from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Zacks Research downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Friday, September 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, September 27th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on 10x Genomics and gave the company a “hold” rating in a report on Friday, August 8th. Finally, Canaccord Genuity Group set a $16.00 target price on 10x Genomics in a report on Monday, August 11th. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, 10x Genomics has an average rating of “Hold” and an average price target of $13.65.

10x Genomics Stock Performance

NASDAQ:TXG opened at $12.75 on Friday. The stock has a 50-day simple moving average of $13.17 and a 200-day simple moving average of $10.99. The stock has a market cap of $1.59 billion, a P/E ratio of -18.21 and a beta of 2.05. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $20.92.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.63. The business had revenue of $172.91 million during the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts predict that 10x Genomics will post -1.43 EPS for the current year.

Insider Transactions at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares of the company’s stock, valued at $4,264,874.67. This trade represents a 6.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,149 shares of company stock valued at $539,865. 9.39% of the stock is currently owned by insiders.

Hedge Funds Weigh In On 10x Genomics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Teacher Retirement System of Texas boosted its stake in 10x Genomics by 6.1% in the second quarter. Teacher Retirement System of Texas now owns 14,931 shares of the company’s stock valued at $173,000 after acquiring an additional 858 shares during the period. Allworth Financial LP boosted its stake in 10x Genomics by 150.4% in the second quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock valued at $26,000 after acquiring an additional 1,364 shares during the period. Blue Trust Inc. boosted its stake in 10x Genomics by 48.1% in the second quarter. Blue Trust Inc. now owns 4,894 shares of the company’s stock valued at $57,000 after acquiring an additional 1,590 shares during the period. GAMMA Investing LLC boosted its stake in 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after acquiring an additional 1,614 shares during the period. Finally, Xponance Inc. boosted its stake in 10x Genomics by 17.4% in the first quarter. Xponance Inc. now owns 12,010 shares of the company’s stock valued at $105,000 after acquiring an additional 1,778 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.